Lonza expanded advanced synthesis capabilities for antibody‑drug conjugates (ADCs) at its Oss, Netherlands site by integrating Synaffix‑derived GlycoConnect, HydraSpace polar spacers and toxSYN linker‑payloads into an end‑to‑end CDMO offering that now supports dual‑payload ADCs and scale‑up to toxicology material. Lonza emphasized site investments in lab infrastructure to support process and analytical development for next‑generation bioconjugates. Separately, Johnson & Johnson committed more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania, signaling large pharma’s continued investment in cellular medicine scale‑up. J&J said the plant will support clinical and commercial supply for cell therapies and is part of a broader industrialization push. Together these moves reflect continued industry emphasis on manufacturing capacity and platform integration to reduce technical risk and speed clinical translation.